We are live on ! Find out more

Profound Medical

PROF

Market cap $240M

6.57 USD

+0.71

12.12%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

6.55

-0.02

0.3%

1 day

12.12%

5 days

17.11%

1 month

13.28%

3 months

-9.38%

6 months

-1.94%

Year to date

-14.23%

1 year

7.35%

5 years

-51.08%

10 years

-33.5%

About: Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Employees: 162

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 23.5%

Neutral 70.6%

Negative 5.9%

Zacks Investment Research

Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade

Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth

New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach

Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth

Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar

TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that Emmy Award-winning television host, health advocate and decorated U.S. Navy veteran, Montel Williams, will join the next Let's Huddle webinar for a discussion with its host, Leonard Wheeler, on November 5, 2026, at 3:00 p.m. ET. Mr. Williams will share his personal perspectives on health advocacy, resilience, informed healthcare decisions and the importance of protecting quality of life.

Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar

Zacks Investment Research

Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?

The mean of analysts' price targets for Profound Medical (PROF) points to a 58.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?

TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real-world performance, clinical differentiation, and platform expansion potential of the TULSA Procedure™ performed using the TULSA-PRO ® system.

TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

Zacks Investment Research

Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?

Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans TORONTO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, is pleased to announce entering into a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX) (“Telix”), a commercial-stage global radiopharmaceutical company. The agreement establishes a framework through which the companies intend to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's advanced prostate-specific membrane antigen (“PSMA”) targeting PET molecular imaging technologies, Gozellix® and Illuccix® 1, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO® platform across the prostate care continuum.

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue

Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47%

Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue

Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference

TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City.

Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference

Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the appointment of Richard Fabian as its new President, effective immediately.

Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President

See News Rankings

Price charts implemented using Lightweight Charts™